Results for "The Role of Distributors in the U.S. Specialty Pharmaceuticals Value Chain"
Reimagining the Pharmaceutical Supply Chain
HDA's President and CEO Chip Davis participated in a panel discussion at The Milken Institute’s 2022 Future of Health Summit entitled, “Reimagining the Pharmaceutical Supply Chain in the United States,” discussing the fundamental resilience of the pharmaceutical supply chain, while exploring the gaps and deepened growing health inequities unearthed by recent public health events.
HDA Statement on FDA Distributor Licensure Proposed Rule
The Healthcare Distribution Alliance (HDA) released the following statement from President and CEO Chester “Chip” Davis Jr., regarding FDA’s proposed rule, issued as required by the Drug Supply Chain Security Act (DSCSA), entitled “National Standards for Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers.”
HDA Urges FDA To Adopt Alternatives to Broad DSCSA Enforcement Discretion
The Healthcare Distribution Alliance (HDA) urged the Food and Drug Administration (FDA) to avoid delaying certain requirements for manufacturers and repackagers to comply with the November 27, 2023, Drug Supply Chain Security Act (DSCSA) deadline, in public comments submitted to the agency.